drug-like

A unique collection of 2534 natural product monomers that meet the "Lipinski's Rule of Five", a powerful tool for HTS and HCS screening;

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

TargetMol created the L4020 NO-PAINS Compound Library that applied the PAINS filter, remaining 9384 small molecules that are suitable for new drug development, signaling pathway research, drug repurposing and other research.

A unique collection of 718 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A collection of 19170 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

Well-chosen quantity: only contains 989 bioactive compounds after careful selection

Diversity: Selected from 1,600,000 drug-like compounds covering rich chemical scaffolds, 5000 compounds representing 5000 scaffolds;

Diversity: Selected from 1,600,000 drug-like compounds, 10000compounds representing 5000 scaffolds selected from a large drug-like chemical source;

For your convenience, there are Diversity Sets of 5,000, 10,000, 15,000, and 20,000 compounds with no structure overlap.

A unique collection of 1150 cytoskeleton-related compounds, can be used for HTS and HCS;

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents;

A unique collection of 573 cancer cell differentiation inducing compounds for high throughput and high content screening;

A unique collection of 2440 compounds with anti-breast cancer therapeutic activity or targeting breast cancer's major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study;

A unique collection of 2120 neurotransmitter receptor compounds, can be used for HTS and HCS screening;

A collection of 27752 bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

A unique collection of 246 fragment-like small molecules for FBDD;

Large quantity: contains 193,000 natural product derivatives and the number is continuously updating;

A collection of 1081 natural product molecules originated from Tibetan medicine, which can be used for high-throughput and high-content screening.

Structurally diverse, medicinally active, and unique chemistry (strong IP potential);

1119 drug fragments,a must-have tool for FBDD;

210 macrocyclic compounds of known activity for high-throughput, high-content screening;

A unique collection of 2400 covalent Inhibitors and other molecules with common warheads like chloroacetyl,2-Chloropropionyl,Acryloyl,sulfonyl fluoride, alkyne,acrylamide, ketocarbonyl,disulfide bond, etc.